ArticleFrontiers in microbiology2026
Structural determinants of the scorpion venom peptide Uy234 govern bactericidal activity and membrane-disruptive properties.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The growth-inhibiting effect of the peptide Uy234, present in the venom of the scorpion Methods: Two inactivated variants were analyzed: Uy234-C, a non-amidated peptide, and Uy234-A, a P9A mutant. In addition to quantifying in detail the minimum inhibitory and bactericidal concentrations for each microorganism, membrane-damaging effects were assessed through bacterial cell viability assays with SYTO9/PI fluorophores. In addition, AFM, electroforming, and GUV microaspiration were used to determine the effects of each peptide in terms of permeabilization. Molecular dynamics (MD) simulations were also performed for the wild-type peptide and its P9A mutant. Results: Only the native peptide Uy234 showed bacteriostatic and bactericidal activity, whereas the P9A mutant and non-amidated variant lost antimicrobial activity, demonstrating the essential role of the Pro-9 residue and C-terminal amidation in Uy234 bioactivity against both pathogens. SYTO9/PI assays in Discussion: Our study provides clear evidence of a damaging effect on the membrane associated with the bioactivity of Uy234. This bioactivity is directly associated with the presence of residue P9 and the presence of C-terminal carboxyamidation. The mutant peptide P9A is unable to permeabilize GUVs, which is consistent with the persistence of a greater degree of structural order, according to MD simulations in the aqueous phase. This study provides a framework for the rational design of bactericidal peptides targeting multidrug-resistant bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.